Research
Retatrutide: Triple-Receptor Agonist Research Report
Retatrutide, a first-in-class triple hormone receptor agonist, has demonstrated unprecedented weight loss efficacy of 24.2% at 48 weeks in Phase 2 clinical trials—substantially exceeding the performance of all currently approved GLP-1-based therapies....
Retatrutide: Triple-Receptor Agonist Research Report
Retatrutide: Triple-Receptor Agonist Research Report
Research Report: TB-500 (Thymosin β-4 Fragment) and BPC-157
Peptides such as TB‑500 (a synthetic 43‑amino‑acid fragment of thymosin β‑4) and BPC‑157 (body protective compound 157) are marketed as research chemicals with purported regenerative benefits. They have attracted attention...
Research Report: TB-500 (Thymosin β-4 Fragment) and BPC-157
Research Report: TB-500 (Thymosin β-4 Fragment) and BPC-157
Retatrutide: Triple-Receptor Agonist Research Report
Retatrutide, a first-in-class triple hormone receptor agonist, has demonstrated unprecedented weight loss efficacy of 24.2% at 48 weeks in Phase 2 clinical trials—substantially exceeding the performance of all currently approved GLP-1-based therapies....
Retatrutide: Triple-Receptor Agonist Research Report
Retatrutide: Triple-Receptor Agonist Research Report
Research Report: TB-500 (Thymosin β-4 Fragment) and BPC-157
Peptides such as TB‑500 (a synthetic 43‑amino‑acid fragment of thymosin β‑4) and BPC‑157 (body protective compound 157) are marketed as research chemicals with purported regenerative benefits. They have attracted attention...